Latest news with #Aquablation
Yahoo
a day ago
- Business
- Yahoo
Aquablation® Therapy's Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the 'Company'), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that Aquablation therapy was assigned a Category I code effective January 1, 2026. The 2026 Medicare Proposed Physician Fee Schedule (PFS) includes payment rates for a new Category I Current Procedural Terminology (CPT) code related to Aquablation therapy. Category I CPT code 52XX1 will replace Category III CPT code 0421T as the primary code for Aquablation therapy. 'Securing a Category I CPT Code marks a major milestone for PROCEPT, the urology community, and the patients we serve,' said Sham Shiblaq, chief commercial officer of PROCEPT BioRobotics. 'This transition recognizes the clinical value and widespread use of Aquablation therapy as we continue to make progress toward becoming the BPH surgical standard of care. The Category I code will further support surgeon adoption and broaden patient access to a treatment that delivers durable symptom relief with a low risk of sexual side effects.' The new CPT Category I Code 52XX1 was assigned a 2026 national Medicare physician proposed payment of 16.14 total RVUs which translates to an approximate national average of $540, under the 2026 proposed Medicare PFS. By comparison, TURP was assigned 15.82 total RVUs which translate to an approximate national average of $529. The PFS Proposed Rule was released on July 14, 2025, and updated payment policies and payment rates for services will be provided for Medicare beneficiaries on or after January 1, 2026. The Proposed Rule release is followed by a public comment period that will close in September 2025 and will culminate in CMS' release of the Final Rule, which is expected to be announced in November 2025 for implementation on January 1, 2026. The Proposed Rule is therefore subject to change. These 2026 proposed rule payment values and RVU assignments can be viewed on the CMS website at: About Aquablation TherapyAquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system's real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient's unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion. About PROCEPT BioRobotics CorporationPROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in such statements. PROCEPT BioRobotics undertakes no obligation to publicly update or revise any forward-looking statements. Important Safety InformationAll surgical treatments have inherent and associated side effects. For a list of potential side effects visit Investor Contact:Matt BacsoVP, Investor Relations and Business in to access your portfolio
Yahoo
07-06-2025
- Health
- Yahoo
HCA Florida Gulf Coast Hospital highlights Men's Health Month
PANAMA CITY, Fla. (WMBB) – June marks the annual National Men's Health Month. To recognize this month, HCA Florida Gulf Coast Hospital seeks to raise awareness for a condition that impacts millions of men: benign prostatic hyperplasia (BPH), or enlarged prostate. According to a news release, the hospital offers Aquablation therapy, a minimally invasive treatment that uses the power of water delivered with robotic precision to remove excess prostate tissue. This approach, which broke through in 2024, is said to be highly effective and uniquely tailored to each patient. Because of this, this therapy offers long-term symptom relief with a lower risk of complications. According to HCA Florida Gulf Coast Hospital, they have successfully treated dozens of patients since implementing this technology. As a commitment to men's health, the hospital is encouraging men in the community to speak with their primary care provider or a urologist, as early evaluation can make a significant difference. 'Men's Health Month is an important time to remind men to take charge of their well-being,' said Chase Christianson, CEO of HCA Florida Gulf Coast Hospital. 'We're proud to offer innovative solutions that not only improve health outcomes but also restore confidence and peace of mind for our patients.' For more information, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
10-04-2025
- Business
- Yahoo
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the 'Company'), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Guests are encouraged to register in advance by clicking HERE. Registration is recommended to secure your spot. Members of PROCEPT BioRobotics' management team presenting include: Reza Zadno – Chief Executive Officer Kevin Waters – Chief Financial Officer Sham Shiblaq – Chief Commercial Officer Barry Templin – Chief Technology Officer Clinical perspectives will also be provided by the following physicians: Dr. Inderbir Gill - Founding Executive Director for USC Urology, Chairman of Urological Cancer Surgery at Keck School of Medicine of USC Dr. Brian Helfand - Division Chief of Urology, Endeavor Health, Associate Chief Scientific Officer at Endeavor Health, Clinical Professor at University of Chicago, Ronald Chez Family and Richard Melman Family Endowed Chairman Dr. Gerald Park - Partner, Kansas City Urology Care A live webcast of the event, as well as an archived recording, will be available on the 'Investors' section of the Company's website at The webcast will be archived and available for replay for at least 90 days after the event. About PROCEPT BioRobotics CorporationPROCEPT BioRobotics' mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. Important Safety InformationAll surgical treatments have inherent and associated side effects. For a list of potential side effects visit Investor Contact:Matt BacsoVP, Investor Relations and Business in to access your portfolio
